










An economic evaluation of routine hepatocellular carcinoma surveillance for high-risk patients using a novel approach to modelling competing risks

Joachim Worthington ^{*1}, Emily He ¹, Michael Caruana ¹, Stephen Wade ¹, Barbara de Graaff ³, Anh Le Tuan Nguyen ^{3,4}, Jacob George ², Karen Canfell ¹, and Eleonora Feletto ¹

¹*The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW*

²*Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and University of Sydney*

³*Menzies Institute for Medical Research, The University of Tasmania, Hobart, Tasmania*

⁴*WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity*

Abstract

Introduction: Liver cancer is the only cancer in Australia for which mortality rates have consistently risen, despite tests to identify high-risk individuals. Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Curative treatment for HCC is typically only available if detected early. Australian clinical guidelines recommend routine 6-monthly ultrasound surveillance, with or without serum alpha-fetoprotein, for individuals with liver cirrhosis. This study assesses the health and economic implications of this recommendation, utilizing novel modeling techniques.

Methods: We designed the *sojourn time density model* mathematical framework to develop a model of the evolving risk of HCC, liver disease, and death based on time since diagnosis, incorporating data on liver decompensation, HCC incidence, and HCC survival, and the impact of surveillance on cancer stage and survival.

Results: We estimated that adherence to 6-monthly ultrasound, with or without alpha-fetoprotein, can increase early-stage diagnosis rates, reducing HCC mortality by 22%. We estimate a cost-effectiveness ratio of \$33,850 per quality-adjusted life-year (QALY) saved for 6-monthly ultrasound HCC surveillance, under the \$50,000/QALY cost-effectiveness threshold. HCC surveillance was also estimated to be cost-effective at any interval from 3-24 months.

Conclusions: These findings support the current clinical guideline recommendation for 6-monthly ultrasound surveillance, affirming its health benefits and cost-effectiveness, and show that alternative surveillance intervals would remain beneficial and cost-effective. Our model may be used to refine surveillance recommendations for other at-risk population subgroups and inform evidence-based clinical practice recommendations, and the framework can be adapted for other epidemiological modelling. Supporting the clinical guidelines and their ongoing development as evidence evolves may be key to reversing increasing HCC mortality rates in Australia, which are predicted to increase by more than 20% by 2040.

*Corresponding author; Joachim.Worthington@sydney.edu.au

Modelling routine HCC surveillance

Funding information:

Cancer Council Australia financially supported this study as part of the Optimising Liver Cancer Control in Australia project, which was funded through the Australian Government Department of Health and Aged Care. These funding agreements ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.

Acknowledgements:

The authors would like to acknowledge the Expert Advisory Group for the Optimising Liver Cancer Control in Australia convened by Cancer Council Australia. We would also like to thank Cancer Council Australia for coordination of this project.

Materials reported in this manuscript, including the modelling and results, were developed to support the Optimising Liver Cancer Control in Australia project and were originally developed and reported in *Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: Appendix D7*, a non-peer reviewed report.

The authors would like to acknowledge the Working Group and Community Reference Group for the Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia. A full list of Working Group members is available in *Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: Appendix I*.

The authors would like to thank the Daffodil Centre Systematic Review team, who provided assistance in reviewing the literature on existing models of HCC and surveillance, as well as Yue He, who gave valuable feedback on the manuscript.

This manuscript uses custom data sets from the Australian Institute of Health and Welfare and the Cancer Institute NSW. We thank the Australian Institute of Health and Welfare and the population-based cancer registries of New South Wales, Victoria, Queensland, Western Australia, South Australia, Tasmania, the Australian Capital Territory and the Northern Territory for the provision of data from the Australian Cancer Database. We would also like to thank the Cancer Institute NSW for their assistance with the data request.

Karen Canfell receives salary funding from the National Health and Medical Research Council Australia (NHMRC Leadership Fellowship APP1194679).

Declaration of conflicts of interest:

Karen Canfell is co-principal investigator (PI) of an investigator-initiated trial of HPV screening in Australia (Compass), which is conducted and funded by the Australian Centre for the Prevention of Cervical Cancer (ACPCC), a government-funded health promotion charity. The ACPCC has previously received equipment and a funding contribution for the Compass trial from Roche Molecular Systems USA. She is also co-PI on a major implementation program, "Elimination of Cervical Cancer in the Western Pacific", which receives support from the Minderoo Foundation and equipment donations from Cepheid Inc.

Michael Caruana is an investigator on an investigator-initiated trial of cytology and primary HPV screening in Australia ('Compass') (ACTRN12613001207707 and NCT02328872), which is conducted and funded by the Australian Centre for the Prevention of Cervical Cancer, a government-funded health promotion charity. Australian Centre for the Prevention of Cervical Cancer has received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and operational support from the Australian Government. However, neither MC nor his institution on his behalf (the Daffodil Centre, a joint venture between Cancer Council NSW and The University of Sydney) receive direct or indirect funding from industry for Compass Australia.

1 Introduction

1.1 Hepatocellular carcinoma and surveillance

Worldwide, liver cancer is the fourth most common cause of cancer death;^[1] in Australia, it is the seventh most common cause of cancer-related death^[2] driven by increasing trends in both liver cancer incidence and mortality.^[3] A key step to improving mortality outcomes is increased detection at early stages, to improve the potential for curative treatment.^[4, 5, 6]

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, can be detected early through routine HCC surveillance. Routine HCC surveillance is typically recommended for high-risk populations.^[7] In Australia, clinical guidelines recommend HCC surveillance with six-monthly ultrasound (US) imaging, with the potential addition of alpha-fetoprotein (AFP) blood testing, for people with compensated liver cirrhosis,^[8, 9] and some population groups with chronic hepatitis B.

Determining appropriate HCC surveillance recommendations poses significant challenges, including identifying health benefits and long-term costs,^[10] appropriate target groups,^[11, 12] and optimal technologies and intervals.^[13] This is needed to develop an economic case for health system investment.

1.2 Modelling and HCC

Epidemiological modelling allows a formal synthesis and extrapolation of data to evaluate the impact of an intervention. This approach has been used to guide investment in cancer control interventions.^[14, 15, 16, 17, 18] For HCC, models can synthesise data sources such as time to liver decompensation and HCC in patients with cirrhosis^[19, 20] and cirrhosis and HCC survival.^[21, 22, 2, 23, 24] This can be combined with clinical data on surveillance outcomes and cost data to provide cost-effectiveness estimates. Economic models of HCC and surveillance are less established than for other cancers,^[15] but are crucial for guiding policy and investment in liver cancer control.

Internationally, modelling studies have analysed a range of populations and interventions for liver cancer control; reviews have been published previously.^[8, 7, 25] Australian modelling has shown that six-monthly US, with or without AFP, is likely cost-effective for patients with cirrhosis,^[10] and biomarker testing can stratify risk to improve cost-effectiveness.^[26] Further modelling which captures detailed progression of liver disease, operates at flexible timescales, and incorporates detailed survival data could refine recommendations for surveillance algorithms.

There are a number of unique considerations for modelling HCC and liver disease, such as the interaction of competing risks of liver decompensation and other liver disease events,^[27, 28] the complex distribution of sojourn times for the development of HCC in cirrhotic patients,^[29] significant comorbidities in the target population,^[30] and short expected survival times for HCC patients.^[31] Simple Markov-style models struggle to capture this complexity, while more complex models such as discrete event simulations^[32, 33, 34], agent-based/microsimulation models,^[35, 14] and semi-Markov models^[36, 37, 38] can be hampered by a lack of data, and typically introduce stochastic elements and increase computation burden. In the absence of detailed health state data, using observable data on the time an individual takes to transition between health states, the *sojourn time*, can improve model fidelity.

1.3 Approach

To address this, we developed the *sojourn time density model* framework. We model the dynamics of the probability density of the sojourn time by health state, tracking both the likelihood of being in a given state and the expected time in that state.

The model is parametrised by the *cause-specific hazard rates*[39, 40] (analogous to *transition intensities*[38]), allowing us to exploit survival data and methods[41] such as Kaplan-Meier estimators[42, 39, 43] and risk ratios.[44] This captures the same detail as typical survival models, with the addition of serial state transitions, and is analogous to semi-Markov and discrete event simulations, but with a deterministic numerical scheme.

1.4 Aims

In this manuscript we describe the model structure and numerical scheme for sojourn time density models. We develop a health-economic model of liver disease and HCC, and evaluate the benefits and costs routine HCC surveillance through six-monthly liver US, with or without AFP testing, compared to no surveillance. We also provide an analysis of the potential impact of varying surveillance intervals.

The modelling described in this manuscript was developed to inform the *Clinical practice guidelines for HCC surveillance for people at high risk in Australia*. [8] The development of these guidelines was led by clinicians in the area of liver disease and liver cancer alongside a multi-disciplinary working party, including healthcare and clinical representatives, representatives with lived experience and other community representatives. This group also informed the aims and structure of this economic analysis.

2 Methods: Sojourn Time Density Model

We now describe the sojourn time density model framework and demonstrate its useful properties. We also develop a numerical scheme for the calculation.

2.1 Sojourn time density modelling

Consider a compartmental model with N possible discrete states labelled $1, 2, \dots, N$, such that at any time $t \in T$ (typically $T = [0, \infty)$) an individual belongs to one of these states. We describe not only the likelihood of an individual being in a given state, but also track the distribution of the length of time spent in that state, the *sojourn time* $\tau \in T$.

Doing so describes a continuous-time random process $\{X_t\}_{t \in T}$ with discrete state space $\{1, 2, \dots, N\}$. This process is defined such that $P(X_t = i) = P(\text{individual in state } i \text{ at time } t)$. We can equivalently define the *jump process* $\{Y_n, T_n\}_{n=0,1,2,\dots}$, such that $Y_n = X_t \forall t \in [T_n, T_{n+1})$, $Y_n \neq Y_{n+1}$. [45]

The *cause-specific hazard rates*

$$\lambda_{i,j}(t, \tau), \quad (1)$$

depending on both the model time t and sojourn time τ , are the key parameters for the model. These are the instantaneous transition rates for an individual in state i to transition to state j , at time t , given that the individual has spent time τ in i without any transitions (i.e. entered state i at time $t - \tau$). By modelling the distribution of τ , we can capture evolving transition rates. The t dependency can capture temporal trends as well as evolving risk with age $a = a_0 + t$ where a_0 is the age at $t = 0$. If there is no possible transition between i and j , then $\lambda_{i,j} = 0$.

Formally, the following should hold:

$$\begin{aligned} \lambda_{i,j}(t, \tau) &= \lim_{\Delta t \rightarrow 0} \frac{1}{\Delta t} P(Y_{n+1} = j, T_{n+1} \in [t, t + \Delta t) | Y_n = i, T_n = t - \tau) \\ &= \lim_{\Delta t \rightarrow 0} \frac{1}{\Delta t} P(X_{t+\Delta t} = j | X_s = i \forall s \in [t - \tau, t), X_{t-\tau} \neq i). \end{aligned} \quad (2)$$

Compare this to the equivalent definition for semi-Markov models, Equation (3) in Krol et al, 2015 [46]. For convenience assume $\lambda_{i,i}(t, \tau) = 0$ (i.e. there are no self-loops).

To track the model state and the sojourn time, we introduce the *density functions for the sojourn time*

$$f_i(t, \tau) : T \times T \rightarrow [0, \infty) \quad (3)$$

for $i = 1, 2, \dots, N$. These are the density functions for the sojourn time τ and the state i at time t . Explicitly, the set of functions $\{f_i(t, \tau)\}_{i=1,2,\dots,N}$ is a *probability density function* on the sample space $(\tau, i) \in T \times \{1, 2, \dots, N\}$, describing the likelihood of being in a particular state with a particular sojourn time at fixed time $t \in T$.

Then we can define the probability mass of X_t

$$P(X_t = i) = \int_0^\infty f_i(t, s) ds =: g_i(t). \quad (4)$$

We should expect that

$$\sum_i g_i(t) = 1 \quad (5)$$

i.e. the total mass probability is 1.

Our goal now is to describe the dynamics of $f_i(t, \tau)$, and then show this definition satisfies (2) and (5). Let $f_i(t, \tau)$ satisfy the partial differential equation

$$\frac{\partial}{\partial t} f_i(t, \tau) + \frac{\partial}{\partial \tau} f_i(t, \tau) = - \left(\sum_j \lambda_{i,j}(t, \tau) \right) f_i(t, \tau) \quad (6)$$

with boundary condition

$$f_i(t, 0) = \sum_j \left(\int_0^\infty \lambda_{j,i}(t, \tau) f_j(t, \tau) d\tau \right). \quad (7)$$

The LHS of equation (6) is motivated by the transport equation along lines of constant $t - \tau$, representing the likelihood of remaining in state i while both t and τ increase, while the RHS captures the likelihood of making a transition to a subsequent state. This can be seen by observing that along the directional derivative

$$\nabla_{(1,1)} f_i = - \left(\sum_j \lambda_{i,j}(t, \tau) \right) f_i(t, \tau) \quad (8)$$

the likelihood decays proportionally to the hazard rate (see Section 2.2). The boundary condition (7) represents the accumulation of probability mass in state i post-transition. By (5), the initial conditions $f_i(0, \tau)$ should satisfy

$$\sum_i \int_0^\infty f_i(0, \tau) d\tau = 1. \quad (9)$$

Additionally,

$$\lim_{\tau \rightarrow \infty} f_i(t, \tau) = 0 \quad (10)$$

(i.e. the model is supported on finite time only; see Section 2.4). For a further discussion of initial conditions, see Appendix C.1.

We now have a complete description of the random process X_t through (4), (6), (7), and appropriate initial conditions. This constitutes what we will call a *sojourn time density model*. These models resemble semi-Markov processes/Markov renewal processes, [38] as the sequence of transitions is Markov (as the next state depends only on the previous state and transition time) but the time between transitions is not.

We now show that the process defined by (4) is well-defined and driven by the hazards $\lambda_{i,j}(t, \tau)$ as expected.

Theorem 2.1. *The random process defined by (4) satisfies conditions (2) and (5).*

Proof. We calculate the derivative of $g_i(t)$, i.e. the rate of change in likelihood of being in state i at time t

$$\begin{aligned} \frac{d}{dt} g_i(t) &= \frac{d}{dt} \int_0^\infty f_i(t, \tau) d\tau \\ &= \int_0^\infty \frac{\partial}{\partial t} f_i(t, \tau) d\tau \\ &= - \int_0^\infty \frac{\partial}{\partial \tau} f_i(t, \tau) d\tau - \int_0^\infty \left(\sum_j \lambda_{i,j}(t, \tau) \right) f_i(t, \tau) d\tau \\ &= f_i(t, 0) - \int_0^\infty \left(\sum_j \lambda_{i,j}(t, \tau) \right) f_i(t, \tau) d\tau \\ &= \underbrace{\sum_j \left(\int_0^\infty \lambda_{j,i}(t, \tau) f_j(t, \tau) d\tau \right)}_{\text{entering state } i} - \underbrace{\int_0^\infty \left(\sum_j \lambda_{i,j}(t, \tau) \right) f_i(t, \tau) d\tau}_{\text{leaving state } i}. \end{aligned} \quad (11)$$

This satisfies the definition the hazard rate - the likelihood of being in state i decreases proportionally to the hazard of every transition leaving state i $\sum_j \lambda_{i,j}(t, \tau)$, and increases for every transition entering state i $\sum_j \lambda_{j,i}(t, \tau)$ proportional to the weight of those states $f_j(t, \tau)$.

Note that

$$\sum_i \frac{d}{dt} g_i(t) = 0, \quad (12)$$

i.e. that the total probability mass is conserved. Therefore with initial conditions satisfying equation (9), (5) is satisfied.

If we know that the system enters state i at time t^* , i.e. (Y_n, T_n) is realised as (i, t^*) and remains there to at least time $t^* + \tau^*$ (i.e. $T_{n+1} - T_n \geq \tau^*$), this corresponds to

$$f_j(t, \tau) = \begin{cases} \delta(t - t^* - \tau) & \text{if } i = j \\ 0 & \text{if } i \neq j \end{cases} \quad (13)$$

for all $t \in [t^*, t^* + \tau^*)$ where $\delta(t)$ is the Dirac delta function. Then

$$\begin{aligned} \frac{d}{dt} g_i(t)|_{t=t^*+\tau^*} &= \left(\sum_j \left(\int_0^\infty \lambda_{j,i}(t^* + \tau^*, \tau) f_j(t^* + \tau^*, \tau) d\tau \right) \right. \\ &\quad \left. - \int_0^\infty \left(\sum_j \lambda_{i,j}(t^* + \tau^*, \tau) \right) f_i(t^* + \tau^*, \tau) d\tau \right) \\ &= \left(- \int_0^\infty \left(\sum_j \lambda_{i,j}(t^* + \tau^*, \tau) \right) \delta(\tau^* - \tau) d\tau \right) \\ &= - \sum_j \lambda_{i,j}(t^* + \tau^*, \tau^*) \end{aligned} \quad (14)$$

and for $j \neq i$

$$\frac{d}{dt} g_j(t)|_{t=t^*+\tau^*} = \lambda_{i,j}(t^* + \tau^*, t^*). \quad (15)$$

In other words, the likelihood of transition out of state i is proportional to the sum of the hazards $\sum_j \lambda_{i,j}$ and the likelihood of transition $i \rightarrow j$ is proportional to $\lambda_{i,j}$. Then

$$\begin{aligned} P(Y_{n+1} = j, T_{n+1} < t + \Delta t | Y_n = i, T_n = t - \tau, T_{n+1} \geq t) \\ &= g_j(t + \Delta t) \\ &\approx g_j(t) + \Delta t \frac{d}{dt} g_j(t) \\ &= \Delta t \lambda_{i,j}(t, \tau) \end{aligned} \quad (16)$$

by the above. By taking the limit $\Delta t \rightarrow 0$, (2) is satisfied. \square

2.2 Method of characteristics and survival analysis

We now compute survival curves using method of characteristics. As noted, equation (6) is best interpreted along characteristics of constant $t - \tau$ corresponding to the state entry time (Figure 1). This allows explicit solutions through method of characteristic, as well as analogies to other survival modelling approaches.¹

¹We refer to *survival* in the sense of *survival analysis*, i.e. the time until an event of interest,[39] not necessarily mortality.




Figure 1: Characteristics of constant $t^* = t - \tau$ for $f_i(t, \tau)$ (left) and the corresponding elements $F_i^{m,n}$ with constant $m - n$ for the numerical scheme (right).

Consider the characteristic $t = t^* + \tau$ for fixed $t^* \in \mathbb{R}$. Then

$$\frac{d}{d\tau} f_i(t^* + \tau, \tau) = \frac{\partial}{\partial t} f_i(t^* + \tau, \tau) \frac{d}{d\tau} (t^* + \tau) + \frac{\partial}{\partial \tau} f_i(t^* + \tau, \tau) \quad (17)$$

$$= - \left(\sum_j \lambda_{i,j}(t^* + \tau, \tau) \right) f_i(t^* + \tau, \tau). \quad (18)$$

If $t^* > 0$, this corresponds to a characteristic starting from the boundary; if $t^* \leq 0$, this corresponds to a characteristic from the initial condition. This has solution

$$f_i(t^* + \tau, \tau) = f_i(t_0, \tau_0) e^{-\Lambda_i(t^* + \tau, \tau)} \quad (19)$$

where $t_0 = \max(t^*, 0)$, $\tau_0 = \max(-t^*, 0)$ (so that $t^* = t_0 - \tau_0$, $t_0, \tau_0 \geq 0$) and

$$\Lambda_i(t, \tau) = \sum_j \left(\int_{\tau_0}^{\tau} \lambda_{i,j}(t - \tau + s, s) ds \right). \quad (20)$$

The function $\Lambda_i(t, \tau)$ is the *all-cause cumulative hazard* along the characteristic $t - \tau = t^*$. Then

$$S_i(t, \tau) = e^{-\Lambda_i(t, \tau)}, \quad (21)$$

is the *all-cause survival* along this characteristic, and $f_i(t^* + \tau, \tau) = f_i(t_0, \tau_0) S_i(t^* + \tau, \tau)$.

We can correspondingly calculate the *time-to-event distribution* after entering state i at time $t - \tau$ as the distribution

$$\lambda_{i,j}(t, \tau) S_i(t, \tau) \quad (22)$$

across $j = 1, 2, \dots, N$.

It follows that the probability of the next transition being before time $t = t^* + \tau$ and also from $i \rightarrow j$, given entry to state i at time t_0 , is:

$$\begin{aligned} & P(\text{next transition time} < t \cap \text{next transition } i \rightarrow j \mid \text{entered state } i \text{ at time } t_0) \\ &= P(Y_{n+1} = j, T_{n+1} < t \mid Y_n = i, T_n = t_0) \\ &= \int_{t_0}^t \lambda_{i,j}(s, s - t^*) S_i(s, s - t^*) ds. \end{aligned} \quad (23)$$

The limit of this is the likelihood of the next transition being to a particular state:

$$\begin{aligned} P(\text{next transition } i \rightarrow j \mid \text{entered state } i \text{ at time } t_0) \\ = \int_{t_0}^{\infty} \lambda_{i,j}(s, s - t^*) S_i(s, s - t^*) ds. \end{aligned} \quad (24)$$

We can also calculate the *cause-specific survival*, assuming other transitions (or events) are censored:

$$S_{i,j}(t, \tau) = e^{-\int_{t_0}^{\tau} \lambda_{i,j}(t - \tau + s, s) ds}. \quad (25)$$

Where cause-specific survival data (equivalently, cause-specific cumulative incidence) is available with competing events censored, this may provide a calibration target for the hazard rates, which can be directly identified from the survival model (see *Hazard and Cumulative hazard* in Clark et al[39]); parametrisation of $\lambda_{i,j}(t, \tau)$ across t^* can then be identified.

Given t^* , the results above are analogous to the functions used for parametric competing risk survival models, time-to-event models, and discrete event models.[47] The sojourn time density model approach generalises this to modelling serial events deterministically. The *all-cause cumulative incidence function* $1 - S_i(t, \tau)$ is used in e.g. Fine-Gray modelling.[48] A useful guide to translating between cause-specific and all-cause specific hazard rates is included in Asanjarani et al,[38] and shows discrete event simulation distributions can be translated into hazard rates. For discrete event simulations where events do not preclude each other, transitions which preserve sojourn time may be added (Appendix C.4).

A common approach in analytical epidemiological models is to compute likelihood of transition as the convolution of the τ -dependent hazard rate and the time of entry.[49, 50] In our formulation, this is reflected in the boundary conditions

$$\begin{aligned} f_i(t, 0) &= \sum_j \left(\int_0^{\infty} \lambda_{j,i}(t, \tau) f_j(t, \tau) d\tau \right) \\ &= \sum_j \left(\int_0^{\infty} f_j(t - \tau, 0) \lambda_{j,i}(t, \tau) S_j(t, \tau) d\tau \right). \end{aligned} \quad (26)$$

If we define entry time distribution $F_j(x) = f_j(x, 0)$ and survival-adjusted cause-specific hazard rate $H(j, i)(x) = \lambda_{j,i}(t, x) S_j(t, x)$, then $F_i(t) = \sum_j (F_j * H_{j,i})(t)$, the convolution of these. We have generalised this approach and incorporated serial transitions.

2.3 Numerical scheme

The characteristic solutions developed in Section 2.2 can be used to develop a numerical scheme. For a discretisation of T by fixed timesteps $\Delta t \in \mathbb{R}^+$, define

$$\begin{aligned} F_i^{m,n} &:= f_i(m\Delta t, n\Delta t) \\ &= \begin{cases} f_i((m-n)\Delta t, 0) e^{-\Lambda_i(m\Delta t, n\Delta t)} & \text{if } m \geq n \\ f_i(0, (n-m)\Delta t) e^{-\Lambda_i(m\Delta t, n\Delta t)} & \text{if } m < n \end{cases} \\ &= \begin{cases} F_i^{m-n,0} e^{-\Lambda_i(m\Delta t, n\Delta t)} & \text{if } m \geq n \\ F_i^{0,n-m} e^{-\Lambda_i(m\Delta t, n\Delta t)} & \text{if } m < n \end{cases} \end{aligned} \quad (27)$$

for $m, n \in \mathbb{Z}^+$. Each value of $m - n$ corresponds to a characteristic $(m - n)\Delta t$. The cumulative hazard functions $\Lambda_i(t, \tau)$ may be computed by (20) in simple cases, or estimated

iteratively by Δt steps. Equivalently, each element can be calculated iteratively by

$$\begin{aligned} F_i^{m,n} &= F^{m-1,n-1} e^{-\sum_j \int_0^{\Delta t} \lambda_{i,j}((m-1)\Delta t+s, (n-1)\Delta t+s)} \\ &\approx F^{m-1,n-1} \left(1 - \sum_j \lambda_{i,j} \left((m - \frac{1}{2})\Delta t, (n - \frac{1}{2})\Delta t \right) \right) \end{aligned} \quad (28)$$

(see Figure 1 for an illustration of this).

For $m < n$, the initial condition is $F_i^{0,n} = f_i(0, n\Delta t)$. For $m > 0$, the initial condition $F_i^{m,0} = f_i(m\Delta t, 0)$ is the boundary conditions of the full PDE. A first order scheme can be computed as

$$\begin{aligned} F_i^{m,0} &= f_i(m\Delta t, 0) \\ &= \sum_j \left(\int_0^\infty \lambda_{j,i}(m\Delta t, \tau) f_j(m\Delta t, \tau) d\tau \right) \\ &\approx \sum_j \left(\sum_{k>0} \Delta t \lambda_{j,i}(m\Delta t, k\Delta t) f_j(m\Delta t, k\Delta t) \right) \\ &= \sum_{k>0, j} \left(\Delta t \lambda_{j,i}(m\Delta t, k\Delta t) F_j^{m,k} \right) \end{aligned} \quad (29)$$

for $m \geq 0$.

One can subsequently approximate

$$\begin{aligned} g_i(m\Delta t) &\approx \sum_{k=0}^\infty \Delta t f_i(m\Delta t, k\Delta t) \\ &\approx \sum_{k=0}^\infty \Delta t F_i^{m,k} \end{aligned} \quad (30)$$

and hence the process X_t .

An improvement can be made to this numerical scheme by adjusting the boundary conditions to exactly preserve the total mass at all timesteps:

$$F_i^{m,0} = \sum_{j,k} \tilde{\lambda}_{j,i}^{m,k} (F_j^{m-1,k-1} - F_j^{m,k}) \quad (31)$$

where

$$\tilde{\lambda}_{i,j}^{m,k} = \frac{\lambda_{i,j}((m - \frac{1}{2})\Delta t, (k - \frac{1}{2})\Delta t)}{\sum_l \lambda_{i,l}((m - \frac{1}{2})\Delta t, (k - \frac{1}{2})\Delta t)}. \quad (32)$$

We can then verify that $\sum_{i,k} F_i^{m,k}$ is constant, i.e. the total probability mass $\sum_i g_i(t)$ is conserved. We have here used the midpoint estimates for $\lambda_{i,j}$, which improves accuracy when there is a significant scale difference between hazards.

In epidemiological contexts, hazards are often modelled as continuous and smooth functions, so this first order numerical scheme will have high accuracy.

2.4 Hazard functions and common parametric distributions

The sojourn time density modelling scheme is determined by the hazard rates $\lambda_{i,j}(t, \tau)$. It is common to describe these rates parameterically.[51] Commonly used parametric forms for these hazard functions include

- constant hazard $\lambda_{i,j}(t, \tau) = c$, corresponding to an exponential time-to-event distribution; if all hazards are constant, X_t is Markov.

- polynomial hazard $\lambda_{i,j}(t, \tau) = bk\tau^{k-1}$, corresponding to a Weibull distribution, often used to model single-cause mortality.[52]
- exponential hazard $\lambda_{i,j}(t, \tau) = pe^{r\tau}$, corresponding to a Gompertz distribution, often used to model of all-cause mortality.[52]

There are many other potential choices for $\lambda_{i,j}(t, \tau)$. It may be useful to define the hazard rate piecewise over t , τ , or both, either piecewise constant or functions.[53] The choice of hazard function is highly dependent on the nature of the system being modelled and the available data sources.[54] Hazard rates can be estimated from processed survival data, typically after smoothing[55] or time-to-event distributions.[38, 56]

Hazard can be adjusted to reflect covariates; Cox proportional hazard ratios can be used to calculate $\lambda_{i,j}(t, \tau | \mathbf{x}) = \lambda_{i,j}(t, \tau | 0)e^{\beta \cdot \mathbf{x}}$ for some covariates $\mathbf{x} \in \mathbb{R}^n$ and a baseline hazard function $\lambda_{i,j}(t, \tau | 0)$. [44, 48] Constant hazard multipliers can be used as calibration targets, to maintain the shape of the distribution,[53] and hazards can be adjusted to reflect lead-time biases in the data (see Appendix C.1). With minor alterations, one can also introduce hazards which are dependent on the current state of the system; for example, this allows for modelling of infectious disease models. See Appendix C.3 for further details.

2.5 Example model

An example sojourn time density model is shown in Figure 2, demonstrating the impact of t - and τ -dependent hazard rates. This model has four states, A , B , C , D . The transitions out of A are $\lambda_{A,B}(t, \tau) = \lambda_{A,C}(t, \tau) = 0.2$, as these are constant, $P(X_t = A)$ decays exponentially, like a Markov process (Figure 3). The subsequent transitions are $\lambda_{B,D}(t, \tau) = 0$ if $\tau < 1$, 5 otherwise, and $\lambda_{C,D}(t, \tau) = 0$ if $t < 2$, 2 otherwise. The impact of the t and τ dependencies can be seen in the evolving density of $f_i(t, \tau)$. The initial condition was $f_A(0, \tau) = 1$ for $\tau \in [0, 1)$. Further examples are included in Appendix C.2.




Figure 2: An example sojourn time density model, showing the evolution of the density of sojourn time. Darker regions have higher density, and lighter regions have lower density. Note how the density in state B sharply decreases at $\tau \geq 1$, and in state C at $t \geq 2$. See Figure 3 for the resulting process.




Figure 3: The resulting process X_t from the model illustrated in Figure 2

3 Methods: Modelling Liver cirrhosis and HCC

We now describe the development of a sojourn time density model of liver disease and HCC. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS)[57] checklist is included in Appendix D.

3.1 Model structure

The structure of the model is illustrated in Figure 4. Individuals start with compensated liver cirrhosis, which can develop into decompensated cirrhosis and/or undiagnosed HCC. These states were selected to capture the most clinically-relevant details based on the available data. Undiagnosed HCC is diagnosed either symptomatically/incidentally or at a routine HCC surveillance event. The Australian liver cirrhosis patient population was modelled.

HCC stage at diagnosis was modelled according to the Barcelona Clinic Liver Cancer (BCLC) staging system,[58] which is based on a patient's Eastern Cooperative Oncology Group (ECOG) performance status,[59] Child-Pugh Score,[60] and tumour stage. Cancers were identified as early (BCLC stage 0/A: ECOG status 0, tumour ≤ 3 cm), intermediate (BCLC stage B: ECOG status 0, multinodular), or late stage (BCLC stage C/D: ECOG status ≥ 1 , vascular invasion, extrahepatic spread, and/or Child-Pugh C). These groupings aligned with available survival data. Patients with compensated cirrhosis initially develop early stage HCC, which can subsequently progress; patients with decompensated cirrhosis develop late stage HCC only. The modelled stage is stage at diagnosis only; post-diagnosis progression is not explicitly modelled, but is reflected in modelling of stage-at-diagnosis survival per the available data.

3.2 Cirrhosis and health state transitions

Decompensation rates for patients with compensated liver cirrhosis were directly available from cohort studies.[61] HCC incidence, diagnosis, and upstaging rates were calibrated based on time-to-event data for HCC diagnosis and observed stage at diagnosis.[61, 62] This was supplemented with data on observed stage at diagnosis in cohorts routinely undergoing HCC surveillance[62] and data on the sensitivity and specificity of HCC surveillance.[63] The full list of sources for the model parameters are included in A.




Figure 4: A simplified schematic of the model of HCC and liver surveillance.

3.3 HCC and other cause survival

Five-year stage-specific overall survival rates were calculated based on data from the NSW Cancer Registry, as these data are stratified by stage,[64] augmented by national data.[65] International studies were used to inform survival by time since diagnosis, by stage, and screen- vs symptomatically-detected HCC.[24] Treatment modalities, including serial treatments, were not modelled explicitly.

HCC recurrence over five years after initial diagnosis was not modelled due to lack of data; HCC recurrence within five years of the initial diagnosis is included in the modelled five-year survival rates. Other-cause mortality was modelled for people with compensated or decompensated cirrhosis [29] relative to the age-specific mortality rate in Australian data.[66]

3.4 Routine HCC surveillance

HCC surveillance is modelled as routine US with or without AFP after the diagnosis of compensated cirrhosis. Six-monthly US with AFP was modelled as the base case, as currently recommended.[8, 67, 68] Diagnosis to confirm suspected HCC, either after symptomatic development or positive surveillance event (including false positives), was modelled as computed tomography or magnetic resonance imaging, with biopsy in cases where imaging was insufficient.[10] People who experience liver decompensation do not receive HCC surveillance, per recommendations.[7] For the purposes of this study, patients were assumed to have perfect uptake and adherence to surveillance, to assess the impact of the surveillance recommendations rather than of patient behaviours.

3.5 Costs and health state utilities

The benefits of surveillance were measured in quality-adjusted life-years. Disutilities were identified for patients with compensated cirrhosis, decompensated cirrhosis, and HCC patients. Disutilities for HCC patients were classified according to their phase of care (diagnostic, ongoing, or terminal), as well as multiplicative existing disutilities due to cirrhosis.[69, 70]

Costs and benefits were analysed from a health system perspective to capture the most relevant cost for Australian governmental policymakers, and presented as 2023 Australian

dollars with costs adjusted using the Australian health CPI index.[71] Costs relating to cancer treatment were based on an excess-cost study which stratified patients by their primary treatment,[23] which varied by stage at diagnosis. These data were chosen as they are locally relevant and based on real-world observations rather than idealised treatment recommendations.

Costs for surveillance and diagnostic procedures were collated from the Australian Medicare Benefits Schedule. Other costs included annual costs of cirrhosis care for patients with and without decompensation, and end-of-life costs.[72, 73] A lifetime time horizon was included to capture the full downstream benefits of surveillance. For the cost-effectiveness analysis, a 5% annual discount rate was applied to both costs and QALYs, in line with other health economic analyses in Australia.[74] A supplementary sensitivity analysis on the impact of the choice of discount rate was completed. Cost inputs are included in Appendix A.

3.6 Parameters and calibration

Parameters were directly derived or calibrated from relevant sources identified in the clinical guidelines,[8] with Australian studies used where possible. Where Australian trial data were not available, the data sources prioritised meta-analyses with large cohort sizes.

Parametric forms for the hazard rates were chosen to best fit the data while minimising the number of parameters to avoid potential overfitting. Where necessary, the Nelder-Mead algorithm was used to determine the best-fit parameters by minimising the mean square error between the model outputs and the target data. Additional methodology is included in Appendix A.

3.7 Scenarios modelled

For the baseline analysis, we estimated the health benefits and economic impacts of 6-monthly HCC surveillance with US, with or without AFP, with no routine HCC surveillance as the comparator. This was modelled for a cohort with mean age 51 (standard deviation 11) to reflect the general cirrhotic population,[75] by aggregating single-age simulations. We calculated HCC stage, likelihood of HCC death, quality-adjusted life expectancy, and costs. A further analysis was conducted to assess the impact the frequency of surveillance.

3.8 Sensitivity analyses

One-way sensitivity analyses and probabilistic sensitivity analyses were conducted to assess the model's sensitivity to key parameters. Additional methodology is included in Appendix B.

3.9 Role of the Funders

Financial support for this study was provided by Cancer Council Australia through a contract as part of a project Optimising Liver Cancer Control in Australia which was funded through the Australian Government Department of Health and Aged Care. The funding agreements ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.

Outcome	No Intervention	6-monthly US	6-monthly US with AFP
HCC incidence per 100,000	21,541	-	-
Proportion of HCC diagnosed at early stage*	47.0%	79.6%	81.3%
HCC mortality per 100,000	14,918	11,680	11,504
Reduction vs no surveillance	-	21.7%	22.9%
Lifetime liver-related healthcare costs per 100,000 (billions)	\$12.91	\$13.63	\$13.68
Increase in costs vs no surveillance	-	5.6%	5.9%
Liver costs per 100,000 (billions, discounted)	\$8.30	\$8.89	\$8.99
Quality-adjusted life expectancy per 100,000	865,630	919,300	922,300
Increase vs no surveillance	-	6.2%	6.5%
Quality-adjusted life expectancy per 100,000 (discounted)	562,200	579,800	581,000
CER vs No Intervention	-	\$33,850	\$36,870
ICER	-	\$33,850	\$81,360

Table 1: Key results for the health benefits and cost-effectiveness of routine HCC surveillance by 6-monthly ultrasound vs no surveillance, with or without AFP. Costs include costs associated with ongoing cirrhosis care, surveillance costs, HCC diagnosis and treatment costs, and end-of-life costs. US - ultrasound. AFP - alpha-fetoprotein. HCC - hepatocellular carcinoma. CER - cost-effectiveness ratio vs no surveillance. ICER - incremental cost-effectiveness ratio vs previously most cost-effective strategy.

4 Results

4.1 Model calibration

The model was calibrated to reproduce key targets (Figure 5). The model was well-fitted to the target data, reproducing the terminal values for the survival curves and remaining within the 95% confidence intervals for the duration of the survival data. The full parameter set for the model is shown in Appendix A, including calibration targets and parameter distributions used in the sensitivity analyses.

4.2 Health benefits and cost-effectiveness of surveillance

The results of the analysis are shown in Table 1. These analyses were for a cirrhotic cohort with no decompensation, and a mean age of 51 ± 11 years. Among those diagnosed with HCC, the probability of being diagnosed at early-stage disease would increase by 81.3% for those that undergo six-monthly US surveillance with AFP.

Six-monthly HCC surveillance with US alone would reduce a person with cirrhosis' likelihood of HCC death by 21.7% compared to no intervention, increasing the quality-adjusted life-expectancy by 6.2%. Six-monthly US with the addition of AFP would reduce likelihood of HCC death by 22.9%, increasing the quality-adjusted life-expectancy by 6.5%. On average, people with cirrhosis would experience 17.6 surveillance events over their lifetime, and have an average total cirrhosis and HCC costs of \$136,324 (2023 AUD), a 5.6% increase compared to those who do not undergo surveillance, with similar increases with the addition of AFP.

The cost-effectiveness of HCC surveillance with six-monthly US would be \$33,850/QALY compared to no surveillance, below the indicative willingness-to-pay threshold of \$50,000/QALY often used in Australia. This indicates that surveillance using six-monthly US would be cost-effective. Six-monthly surveillance with US and AFP would have a very similar cost-effectiveness of \$36,860/QALY compared to no surveillance and be




Figure 5: Key calibration outputs. From top to bottom: HCC incidence rates (left; target Vilar Gomez 2018 [61]) and decompensation rates (right); all-cause death rates in patients with compensated (left; includes any decompensation events) and decompensated (right) cirrhosis; HCC stage at diagnosis with (left) and without (right) routine HCC surveillance.




Figure 6: Discounted costs vs discounted QALYs saved for routine ultrasound surveillance with alpha-fetoprotein by surveillance interval in months, from 1 month to 48 months.

cost-effective. The incremental cost-effectiveness ratio of US with AFP vs US alone would be \$81,360/QALY, indicating it is unlikely to be an incrementally cost-effective compared to offering US only.

The impact of varying the interval for routine US is shown in Figure 6. Shorter surveillance intervals have higher benefits, but at correspondingly higher costs. Surveillance intervals of 7 months or longer had cost-effectiveness ratio under \$30,000/QALY for US with or without AFP. Additional benefits and costs are in very similar proportions at intervals over 12 months, while shorter intervals led diminishing benefits per cost increase. The addition of AFP was approximately equivalent to extending the surveillance interval by 1-3 months.

The results of the one-way sensitivity analysis found that the cost-effectiveness was most sensitive to parameters regarding early-stage HCC, including 5-year survival for Stage 0/A HCC and the proportion of HCCs diagnosed at Stage 0/A. The probabilistic sensitivity analysis found that six-monthly US was cost-effective in the 85.5% of simulations, demonstrating that this result is robust to parameter uncertainty. The analysis of the discount rate found that lower discount rates led to more favourable cost-effectiveness, due to the long-term benefits of surveillance. The full results are included in Appendix B.

5 Discussion

We described the development of a model of HCC surveillance in Australians with liver cirrhosis. This leverages a novel mathematical approach to simulating the sojourn time allowing detailed survival data sources to be used and short timescale events to be modelled. The model was calibrated to capture health outcomes and costs and reproduced the targets to a high level of precision.

Our findings indicate that routine HCC surveillance with six-monthly US with perfect adherence would be cost-effective and reduce the likelihood of HCC death. These results align with similar recent cost-effectiveness studies in Australia[10] and internationally[25, 8]. This analysis found that the addition of AFP would have further health benefits and would be cost-effective compared to no surveillance, but would not be incrementally cost-effective; there was a high degree of uncertainty around this outcome, as demonstrated by the included sensitivity analyses. Earlier versions of these findings were included in the *Clinical practice guidelines for HCC surveillance for people at high risk in Australia*[8] to support recommendations for the provision of US surveillance, which were endorsed by the Australian Government National Health and Medical Research Council in 2023.

We also analysed the impact of differing surveillance intervals, finding that routine HCC surveillance at an interval of 7 months or longer would be cost-effective under a \$30,000/QALY threshold, while intervals of 3 months or longer would be cost-effective under a \$50,000/QALY threshold. These findings indicate that the current six-month interval recommendation is appropriate, but also longer intervals would remain cost-effective and still have some health benefits. Longer surveillance intervals caused by patient noncompliance, delays, resource limitations, or other reasons would therefore remain cost-effective and have health benefits. There is limited longitudinal data on liver surveillance compliance with small sample sizes;[76] however, a correlation between compliance and HCC survival has been observed.[77] We also found that the addition of AFP may allow for similar benefits and costs as US alone at a longer interval.

The novel sojourn time density model structure allows for flexible analyses which rely on detailed survival data and flexible timescales. Most liver cancer models are Markov models,[8, 7] which may not be able to exploit complex survival data or reflect detailed disease progression.[78, 79] Liver disease states, both as clinically reported and as typically modelled, are usually a set of well-defined discrete disease states which serve as proxies for a more complex continuous spectrum of disease, such as HCC staging which simplifies variables such as the number and size of tumours, liver function, and other factors. Approaches to address this, like hidden states,[80] can increase the potential detail at the cost of interpretability. Modelling sojourn times based on survival data can reduce reliance on unobservable states and the reliance on detailed calibrations and potential for overfitting. By using the hazard rates as model parameters, the model can be interpreted directly in the context of source epidemiology studies, and parameter values can be directly inferred from survival data. Our approach to modelling also avoids relying on a fixed time discretisation, which could lead to numerical errors if chosen poorly[34] and can limit a model's ability to capture short-timescale events such as late-stage HCC survival without recalibration. This may limit the model's ability to reflect the true health benefits of early-stage diagnosis. Our model can be numerically evaluated at any timescale, allowing us to make simulate surveillance intervals which were not been included in real-world trials.

Alternative model structures such as discrete event simulations[32, 33, 34], which are commonly used in cancer modelling, [18, 81, 82, 83, 84] agent-based/microsimulation models,[35, 14] and semi-Markov models[36, 37, 38] can allow for complex distributions of times between health states. However, these typically require stochastic evaluation,[38, 85, 86] which slows model performance and therefore limits the capacity for iterative model design and methods which explore wide parameter spaces, such as probabilistic sensitivity analysis. Designing models that reduce computational burden to facilitate probabilistic

sensitivity analyses has been identified as a priority for health technology assessments,[87] with surrogate methods such as metamodeling reducing the reliance on larger models.[88, 89, 90] Our approach is fully deterministic and uses a simple numerical scheme, avoiding long runtimes as well as the need for sampling. It is also very flexible, with the capacity to capture a wide range of simulations, and can be expanded to capture systems such as infectious disease models as well (see Appendix C.3).

There is great potential to refine survival analysis estimates designed to guide policy recommendations,[91] and it is hoped that this modelling approach allows for the development of straightforward models which incorporate existing data sources in a clear and flexible way, reducing the need for model calibration and minimising data post-processing and model design effort. The benefits of this approach are demonstrated in the closeness-of-fit to the calibration targets (Figure 5) as well as the flexibility to evaluate surveillance at a wide range of intervals (Figure 6).

In future, this model will be used to analyse combinations of surveillance technologies and intervals. This will allow us to analyse more complex surveillance algorithms, such as the FIB-4 algorithm recommended by the Asian Pacific Association for the Study of the Liver clinical guidelines,[92] and optimise these algorithms through iterative design enabled by the fast computation time and high precision.

The limitations of this model structure include the semi-Markov property; each state transition depends only on the current state, the sojourn time, and the model time. This approach may therefore not be appropriate in contexts where multiple prior events are required to inform future likelihoods, with the number of states needed to represent these growing exponentially.

This model considers only the Australian population with liver cirrhosis. Liver cirrhosis is typically attributable to chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, metabolic-associated fatty liver disease, or a combination of these. Each of these groups have differing HCC risks, potentially differing treatment needs,[93] and differing prevalence in the Australian population.[11, 94] Although these groups are included in the aggregate liver cirrhosis population modelled here, they are not modelled explicitly by aetiology. Future model expansions to capture these risk groups explicitly, will allow more precise cost-effectiveness estimates and recommendations by group, identifying the optimal benefit of health benefits and costs between surveillance technology options and varying intervals.

Another limitation of our model is that treatment is not explicitly modelled by modality; patients are instead modelled based on aggregate survival and costs by stage at diagnosis. Although this is in line with many other models of cancer and surveillance,[15] models of HCC treatment can provide additional detail, particularly regarding health service utilisation.[10] Another limitation is the uncertainty around appropriate willingness-to-pay thresholds for Australia, with both \$30,000 and \$50,000 per QALY used. The interpretation of these results should consider the context to determine the appropriate threshold.

The current simulation of the influence of age on HCC risk was limited by a lack of data. Currently, the modelled age influences HCC risk through time exposed to cirrhosis and risk of other-cause mortality. Incorporating further targets for the evolving risk of HCC and stage at diagnosis would improve the cost-effectiveness estimates and help refine recommendations. In general, data regarding HCC development and surveillance is limited; for example, differences in estimated stage at diagnosis,[62, 95] with significant differences likely attributable to surveillance adherence and patient cohorts, and sensitivity and specificity of US.[96, 63] As further data are made available, modelling will be updated and refined to help guide interventions.

6 Conclusions

There is great potential for routine HCC surveillance to improve mortality outcomes in Australia. However, any recommendations must account for the costs and the consequences of the lower life expectancy and quality-of-life for high-risk individuals. Our robust and flexible model of liver disease and surveillance can estimate the impact of surveillance interventions and inform planning and policy in this area. Future evaluations will provide refinements and extensions of the economic evaluations to capture detailed patient risk groups and alternative surveillance modalities.

References

- [1] Ju Dong Yang et al. “A global view of hepatocellular carcinoma: trends, risk, prevention and management”. *Nature reviews Gastroenterology & hepatology* 16.10 (2019), pp. 589–604. DOI: [10.1038/s41575-019-0186-y](https://doi.org/10.1038/s41575-019-0186-y).
- [2] Michael C Wallace et al. “Hepatocellular carcinoma in Australia 1982-2014: Increasing incidence and improving survival”. *Liver International* 39.3 (2019), pp. 522–530. DOI: [10.1111/liv.13966](https://doi.org/10.1111/liv.13966).
- [3] Qingwei Luo et al. “Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study”. *The Lancet Public Health* 7.6 (2022), e537–e548. DOI: [10.1016/S2468-2667\(22\)00090-1](https://doi.org/10.1016/S2468-2667(22)00090-1).
- [4] Amit G Singal, Pietro Lampertico, and Pierre Nahon. “Epidemiology and surveillance for hepatocellular carcinoma: New trends”. *Journal of hepatology* 72.2 (2020), pp. 250–261. DOI: [10.1016/j.jhep.2019.08.025](https://doi.org/10.1016/j.jhep.2019.08.025).
- [5] Morris Sherman. “Surveillance for hepatocellular carcinoma”. *Best Practice & Research Clinical Gastroenterology* 28.5 (2014), pp. 783–793. DOI: [10.1016/j.bpg.2014.08.008](https://doi.org/10.1016/j.bpg.2014.08.008).
- [6] Daniel Q Huang et al. “Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology”. *Nature Reviews Gastroenterology & Hepatology* (2023), pp. 1–13. DOI: [10.1038/s41575-023-00818-8](https://doi.org/10.1038/s41575-023-00818-8).
- [7] Samuel Hui et al. “Hepatocellular carcinoma surveillance in Australia: current and future perspectives”. *Medical Journal of Australia* 219 (2023), pp. 432–438. DOI: <https://doi.org/10.5694/mja2.52124>. URL: <https://onlinelibrary.wiley.com/doi/abs/10.5694/mja2.52124>.
- [8] Cancer Council Australia Hepatocellular Carcinoma Surveillance Working Group. *Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia*. Sydney, Cancer Council Australia, 2023. URL: <https://www.cancer.org.au/clinical-guidelines/liver-cancer/hepatocellular-carcinoma>.
- [9] John S Lubel et al. “Australian consensus recommendations for the management of hepatitis B”. *Medical Journal of Australia* 216.9 (2022), pp. 478–486. DOI: [10.5694/mja2.51430](https://doi.org/10.5694/mja2.51430).
- [10] Anh Le Tuan Nguyen et al. “Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study”. *BMC Health Services Research* 23.1 (2023), pp. 1–15. DOI: [10.1186/s12913-023-09360-4](https://doi.org/10.1186/s12913-023-09360-4).
- [11] Yuen Kang Joseph Yeoh et al. “Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia”. *Internal Medicine Journal* n/a.n/a (2023). DOI: <https://doi.org/10.1111/imj.16252>. eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.16252>. URL: <https://onlinelibrary.wiley.com/doi/abs/10.1111/imj.16252>.
- [12] The Daffodil Centre. *Preventing liver cancer: obesity and alcohol consumption*. Sydney; The Daffodil Centre and The Australian Prevention Partnership Centre, 2023. URL: <https://preventioncentre.org.au/resources/preventing-liver-cancer-obesity-and-alcohol-consumption/>.
- [13] Grace Lai-Hung Wong. “Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet”. *World journal of hepatology* 7.18 (2015), p. 2133. DOI: [10.4254/wjh.v7.i18.2133](https://doi.org/10.4254/wjh.v7.i18.2133).
- [14] Jie-Bin Lew et al. “Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study”. *The Lancet Public Health* 2.7 (2017), e331–e340. DOI: [10.1016/S2468-2667\(17\)30105-6](https://doi.org/10.1016/S2468-2667(17)30105-6).

- [15] Jie-Bin Lew et al. “Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates”. *Public health research & practice* 29.2 (2019). DOI: [10.17061/phrp2921913](https://doi.org/10.17061/phrp2921913).
- [16] Joachim Worthington et al. “Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia”. *Public health* 179 (2020), pp. 90–99. DOI: [10.1016/j.puhe.2019.10.003](https://doi.org/10.1016/j.puhe.2019.10.003).
- [17] Michaela T Hall et al. “The projected timeframe until cervical cancer elimination in Australia: a modelling study”. *The Lancet Public Health* 4.1 (2019), e19–e27. DOI: [10.1016/S2468-2667\(18\)30183-X](https://doi.org/10.1016/S2468-2667(18)30183-X).
- [18] Michael Caruana et al. “Benefits and harms of prostate specific antigen testing according to Australian guidelines”. *International Journal of Cancer* (2023). DOI: [10.1002/ijc.34731](https://doi.org/10.1002/ijc.34731).
- [19] Anany Gupta et al. “Assessing the risk of further decompensation and survival in patients with cirrhosis with variceal bleeding as their first decompensation event”. *The American Journal of Gastroenterology* 118.5 (2022), pp. 833–839. DOI: [10.14309/ajg.0000000000002018](https://doi.org/10.14309/ajg.0000000000002018).
- [20] Kate M Fleming et al. “The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study”. *Alimentary pharmacology & therapeutics* 32.11-12 (2010), pp. 1343–1350. DOI: [10.1111/j.1365-2036.2010.04473.x](https://doi.org/10.1111/j.1365-2036.2010.04473.x).
- [21] Katherine A McGlynn and W Thomas London. “The global epidemiology of hepatocellular carcinoma: present and future”. *Clinics in liver disease* 15.2 (2011), pp. 223–243. DOI: [10.1016/j.cld.2011.03.006](https://doi.org/10.1016/j.cld.2011.03.006).
- [22] Anh Le Tuan Nguyen et al. “Survival of primary liver cancer for people from culturally and linguistically diverse backgrounds in Australia”. *Cancer Epidemiology* 81 (2022), p. 102252. DOI: [10.1016/j.canep.2022.102252](https://doi.org/10.1016/j.canep.2022.102252).
- [23] Thai P Hong. “An Australian population-based study of the incidence and outcomes of hepatocellular carcinoma: the hepatomas of melbourne epidemiological research (homer) study”. PhD thesis. University of Melbourne, 2019. URL: <http://hdl.handle.net/11343/225659>.
- [24] Mohammad Inamul Haq et al. “Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study”. *Journal of clinical medicine* 10.13 (2021), p. 2770. DOI: [10.3390/jcm10132770](https://doi.org/10.3390/jcm10132770).
- [25] Anh Le Tuan Nguyen et al. “A systematic review and narrative synthesis of Health economic evaluations of Hepatocellular Carcinoma screening strategies”. *Value in Health* 24.5 (2021), pp. 733–743. DOI: [10.1016/j.jval.2020.11.014](https://doi.org/10.1016/j.jval.2020.11.014).
- [26] Hannah E Carter et al. “Cost-effectiveness of a serum biomarker test for risk-stratified liver ultrasound screening for hepatocellular carcinoma”. *Value in Health* 24.10 (2021), pp. 1454–1462. DOI: [10.1016/j.jval.2021.04.1286](https://doi.org/10.1016/j.jval.2021.04.1286).
- [27] Gennaro D’Amico et al. “Clinical states of cirrhosis and competing risks”. *Journal of hepatology* 68.3 (2018), pp. 563–576. DOI: [10.1016/j.jhep.2017.10.020](https://doi.org/10.1016/j.jhep.2017.10.020).
- [28] Peter Jepsen, Hendrik Vilstrup, and Per Kragh Andersen. “The clinical course of cirrhosis: the importance of multistate models and competing risks analysis”. *Hepatology* 62.1 (2015), pp. 292–302. DOI: [10.1002/hep.27598](https://doi.org/10.1002/hep.27598).
- [29] Gennaro D’Amico, Guadalupe Garcia-Tsao, and Luigi Pagliaro. “Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies”. *Journal of hepatology* 44.1 (2006), pp. 217–231. DOI: [10.1016/j.jhep.2005.10.013](https://doi.org/10.1016/j.jhep.2005.10.013).

- [30] Peter Jepsen. “Comorbidity in cirrhosis”. *World Journal of Gastroenterology* 20.23 (2014), pp. 7223–7230. DOI: [10.3748/wjg.v20.i23.7223](https://doi.org/10.3748/wjg.v20.i23.7223).
- [31] Pegah Golabi et al. “Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities”. *Medicine* 96.9 (2017). DOI: [10.1097/MD.0000000000005904](https://doi.org/10.1097/MD.0000000000005904).
- [32] Koen Degeling et al. “Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients”. *Cancer epidemiology* 57 (2018), pp. 60–67. DOI: [10.1016/j.canep.2018.09.008](https://doi.org/10.1016/j.canep.2018.09.008).
- [33] John Graves et al. “Comparison of decision modeling approaches for health technology and policy evaluation”. *Medical Decision Making* 41.4 (2021), pp. 453–464. DOI: [10.1177/0272989X21995805](https://doi.org/10.1177/0272989X21995805).
- [34] Lachlan Standfield, Tracy Comans, and Paul Scuffham. “Markov modeling and discrete event simulation in health care: a systematic comparison”. *International journal of technology assessment in health care* 30.2 (2014), pp. 165–172. DOI: [10.1017/S0266462314000117](https://doi.org/10.1017/S0266462314000117).
- [35] Çağlar Çağlayan et al. “Microsimulation modeling in oncology”. *JCO clinical cancer informatics* 2 (2018), pp. 1–11. DOI: [10.1200/CCI.17.00029](https://doi.org/10.1200/CCI.17.00029).
- [36] Christel Castelli et al. “Cost-effectiveness analysis in colorectal cancer using a semi-Markov model”. *Statistics in medicine* 26.30 (2007), pp. 5557–5571. DOI: [10.1002/sim.3112](https://doi.org/10.1002/sim.3112).
- [37] Ash Bullement, Holly L Cranmer, and Gemma E Shields. “A review of recent decision-analytic models used to evaluate the economic value of cancer treatments”. *Applied health economics and health policy* 17.6 (2019), pp. 771–780. DOI: [10.1007/s40258-019-00513-3](https://doi.org/10.1007/s40258-019-00513-3).
- [38] Azam Asanjarani, Benoit Liquet, and Yoni Nazarathy. “Estimation of semi-Markov multi-state models: a comparison of the sojourn times and transition intensities approaches”. *The international journal of biostatistics* 18.1 (2021), pp. 243–262. DOI: [10.1515/ijb-2020-0083](https://doi.org/10.1515/ijb-2020-0083).
- [39] Taane G Clark et al. “Survival analysis part I: basic concepts and first analyses”. *British journal of cancer* 89.2 (2003), pp. 232–238. DOI: [10.1038/sj.bjc.6601118](https://doi.org/10.1038/sj.bjc.6601118).
- [40] David W Hosmer Jr, Stanley Lemeshow, and Susanne May. *Applied survival analysis: regression modeling of time-to-event data*. John Wiley & Sons, 2011.
- [41] Nicholas R Latimer. “Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide”. *Medical Decision Making* 33.6 (2013), pp. 743–754. DOI: [10.1177/0272989X12472398](https://doi.org/10.1177/0272989X12472398).
- [42] Edward L Kaplan and Paul Meier. “Nonparametric estimation from incomplete observations”. *Journal of the American statistical association* 53.282 (1958), pp. 457–481.
- [43] Manish Kumar Goel, Pardeep Khanna, and Jugal Kishore. “Understanding survival analysis: Kaplan-Meier estimate”. *International journal of Ayurveda research* 1.4 (2010), p. 274. DOI: [10.4103/0974-7788.76794](https://doi.org/10.4103/0974-7788.76794).
- [44] David Roxbee Cox and David Oakes. *Analysis of survival data*. Vol. 21. CRC press, 1984.
- [45] Anastasis Georgoulas, Jane Hillston, and Guido Sanguinetti. “Unbiased Bayesian inference for population Markov jump processes via random truncations”. *Statistics and computing* 27 (2017), pp. 991–1002. DOI: [10.1007/s11222-016-9667-9](https://doi.org/10.1007/s11222-016-9667-9).

- [46] Agnieszka Król and Philippe Saint-Pierre. “SemiMarkov: an R package for parametric estimation in multi-state semi-Markov models”. *Journal of Statistical Software* 66 (2015), pp. 1–16. DOI: [10.18637/jss.v066.i06](https://doi.org/10.18637/jss.v066.i06).
- [47] Wayne Nelson. “Theory and applications of hazard plotting for censored failure data”. *Technometrics* 14.4 (1972), pp. 945–966.
- [48] Jason P Fine and Robert J Gray. “A proportional hazards model for the subdistribution of a competing risk”. *Journal of the American statistical association* 94.446 (1999), pp. 496–509. DOI: [10.2307/2670170](https://doi.org/10.2307/2670170).
- [49] Paul F Pinsky. “An early-and late-stage convolution model for disease natural history”. *Biometrics* 60.1 (2004), pp. 191–198. DOI: [10.1111/j.0006-341X.2004.00023.x](https://doi.org/10.1111/j.0006-341X.2004.00023.x).
- [50] Seth Flaxman et al. “Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe”. *Nature* 584.7820 (2020), pp. 257–261. DOI: [10.1038/s41586-020-2405-7](https://doi.org/10.1038/s41586-020-2405-7).
- [51] Rob C van Wijk and Ulrika SH Simonsson. “Finding the right hazard function for time to event modelling: a tutorial and Shiny app”. *CPT pharmacometrics & systems pharmacology* 11 (2022), pp. 991–1001. DOI: [10.1002/psp4.12797](https://doi.org/10.1002/psp4.12797).
- [52] David A Juckett and Barnett Rosenberg. “Comparison of the Gompertz and Weibull functions as descriptors for human mortality distributions and their intersections”. *Mechanisms of ageing and development* 69.1-2 (1993), pp. 1–31. DOI: [10.1016/0047-6374\(93\)90068-3](https://doi.org/10.1016/0047-6374(93)90068-3).
- [53] AJ Coldman et al. “Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada”. *Current Oncology* 22.2 (2015), pp. 41–50. DOI: [10.3747/co.22.2013](https://doi.org/10.3747/co.22.2013).
- [54] David G Kleinbaum et al. “Parametric survival models”. *Survival Analysis: A Self-Learning Text* (2012), pp. 289–361. DOI: [10.1007/978-1-4419-6646-9_7](https://doi.org/10.1007/978-1-4419-6646-9_7).
- [55] Jane-Ling Wang et al. “Smoothing hazard rates”. *Encyclopedia of Biostatistics* 7 (2005), pp. 4986–4997. DOI: [10.1002/9781118445112.stat06057](https://doi.org/10.1002/9781118445112.stat06057).
- [56] Changbin Guo and Ying So. *Cause-specific analysis of competing risks using the PHREG procedure. SAS Institute Inc. 2018. Paper No.: SAS2159-2018.*
- [57] Don Husereau et al. “Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force”. ENG. *Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research* 25.1 (Jan. 2022). ISSN: 1524-4733. DOI: [10.1016/j.jval.2021.10.008](https://doi.org/10.1016/j.jval.2021.10.008).
- [58] Josep M Llovet, Concepció Brú, and Jordi Bruix. “Prognosis of hepatocellular carcinoma: the BCLC staging classification”. *Seminars in liver disease*. Vol. 19. 03. Thieme Medical Publishers, Inc. 1999, pp. 329–338. DOI: [10.1055/s-2007-1007122](https://doi.org/10.1055/s-2007-1007122).
- [59] Martin M Oken et al. “Toxicity and response criteria of the Eastern Cooperative Oncology Group”. *American journal of clinical oncology* 5.6 (1982), pp. 649–656.
- [60] Ying Peng, Xingshun Qi, and Xiaozhong Guo. “Child–Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies”. *Medicine* 95.8 (2016).
- [61] Eduardo Vilar-Gomez et al. “Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study”. *Gastroenterology* 155.2 (2018), pp. 443–457. DOI: [10.1053/j.gastro.2018.04.034](https://doi.org/10.1053/j.gastro.2018.04.034).

- [62] Yi Huang et al. “Rate of nonsurveillance and advanced hepatocellular carcinoma at diagnosis in chronic liver disease”. *Journal of Clinical Gastroenterology* 52.6 (2018), pp. 551–556. DOI: [10.1097/MCG.0000000000000916](https://doi.org/10.1097/MCG.0000000000000916).
- [63] Kristina Tzartzeva et al. “Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis”. *Gastroenterology* 154.6 (2018), pp. 1706–1718. DOI: [10.1053/j.gastro.2018.01.064](https://doi.org/10.1053/j.gastro.2018.01.064).
- [64] *Annual NSW cancer incidence and mortality data set, 2017 (sourced from the NSW Cancer Registry)*.
- [65] *Australian cancer incidence and mortality data set, 2022 (sourced from the Australian Institute of Health and Welfare)*.
- [66] Australian Bureau of Statistics. *Life Tables*. Australian Bureau of Statistics, 2022. URL: <https://www.abs.gov.au/statistics/people/population/life-tables/latest-release#cite-window1>.
- [67] European Association For The Study Of The Liver et al. “EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma”. *Journal of hepatology* 56.4 (2012), pp. 908–943. DOI: [10.1016/j.jhep.2011.12.001](https://doi.org/10.1016/j.jhep.2011.12.001).
- [68] Hitoshi Yoshiji et al. “Evidence-based clinical practice guidelines for liver cirrhosis 2020”. *Journal of Gastroenterology* 56.7 (2021), pp. 593–619. DOI: [10.1007/s00535-021-01788-x](https://doi.org/10.1007/s00535-021-01788-x).
- [69] Theo Vos et al. “Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019”. *The Lancet* 396.10258 (2020), pp. 1204–1222. DOI: [10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9).
- [70] Steven M McPhail et al. “Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis”. *JGH Open* 5.1 (2021), pp. 133–142. DOI: [10.1002/jgh3.12462](https://doi.org/10.1002/jgh3.12462).
- [71] Australian Bureau of Statistics. *Consumer Price Index, Australia*. Australian Bureau of Statistics, 2023. URL: <https://www.abs.gov.au/statistics/economy/price-indexes-and-inflation/consumer-price-index-australia/latest-release>.
- [72] Yinzong Xiao et al. “Enhancing the hepatitis B care cascade in Australia: a cost-effectiveness model”. *Journal of Viral Hepatitis* 27.5 (2020), pp. 526–536. DOI: [10.1111/jvh.13252](https://doi.org/10.1111/jvh.13252).
- [73] Rebecca Reeve et al. “Health care use and costs at the end of life: a comparison of elderly Australian decedents with and without a cancer history”. *BMC palliative care* 17 (2018), pp. 1–10.
- [74] Centre for Health Economics Research and Evaluation. *Review of discount rate in the PBAC guidelines - phase 1 consultation*. May 2022. URL: <https://ohta-consultations.health.gov.au/ohta/review-of-discount-rate-in-the-pbac-guidelines/>.
- [75] Krishna C Sajja, Desh P Mohan, and Don C Rockey. “Age and ethnicity in cirrhosis”. *Journal of Investigative Medicine* 62.7 (2014), pp. 920–926. DOI: [10.1097/JIM.000000000000106](https://doi.org/10.1097/JIM.000000000000106).
- [76] Nicole Allard et al. “The challenge of liver cancer surveillance in general practice: Do recall and reminder systems hold the answer?” *Australian Family Physician* 46.11 (2017), pp. 859–864.
- [77] Charlotte E Costentin et al. “Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study”. *Gastroenterology* 155.2 (2018), pp. 431–442. DOI: [10.1053/j.gastro.2018.04.027](https://doi.org/10.1053/j.gastro.2018.04.027).

- [78] Frank A Sonnenberg and J Robert Beck. “Markov models in medical decision making: a practical guide”. *Medical decision making* 13.4 (1993), pp. 322–338. DOI: [10.1177/0272989X9301300409](https://doi.org/10.1177/0272989X9301300409).
- [79] Andrea Carta and Claudio Conversano. “On the use of Markov models in pharmacoeconomics: pros and cons and implications for policy makers”. *Frontiers in public health* 8 (2020), p. 569500. DOI: [10.3389/fpubh.2020.569500](https://doi.org/10.3389/fpubh.2020.569500).
- [80] Walter Zucchini, Iain L MacDonald, and Roland Langrock. *Hidden Markov models for time series: an introduction using R*. CRC press, 2017.
- [81] Sally C Brailsford, Paul R Harper, and Jennifer Sykes. “Incorporating human behaviour in simulation models of screening for breast cancer”. *European Journal of Operational Research* 219.3 (2012), pp. 491–507. DOI: [10.1016/j.ejor.2011.10.041](https://doi.org/10.1016/j.ejor.2011.10.041).
- [82] Koen Degeling et al. “Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer”. *Value in health* 25.1 (2022), pp. 104–115. DOI: [10.1016/j.jval.2021.07.016](https://doi.org/10.1016/j.jval.2021.07.016).
- [83] Tracey England et al. “Modelling lung cancer diagnostic pathways using discrete event simulation”. *Journal of Simulation* 17.1 (2023), pp. 94–104. DOI: [10.1080/17477778.2021.1956866](https://doi.org/10.1080/17477778.2021.1956866).
- [84] Paul Robert Harper and SK Jones. “Mathematical models for the early detection and treatment of colorectal cancer”. *Health Care Management Science* 8 (2005), pp. 101–109. DOI: [10.1007/s10729-005-0393-7](https://doi.org/10.1007/s10729-005-0393-7).
- [85] Anders Klevmarken. *Micro Simulation - A Tool for Economic Analysis*. Tech. rep. Working paper, 2001.
- [86] Paul A Gagniuc. *Markov chains: from theory to implementation and experimentation*. John Wiley & Sons, 2017.
- [87] Karl Claxton et al. “Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra”. *Health economics* 14.4 (2005), pp. 339–347. DOI: [10.1002/hec.985](https://doi.org/10.1002/hec.985).
- [88] Hendrik Koffijberg et al. “Using metamodeling to identify the optimal strategy for colorectal cancer screening”. *Value in health* 24.2 (2021), pp. 206–215. DOI: [10.1016/j.jval.2020.08.2099](https://doi.org/10.1016/j.jval.2020.08.2099).
- [89] Koen Degeling, Maarten J IJzerman, and Hendrik Koffijberg. “A scoping review of metamodeling applications and opportunities for advanced health economic analyses”. *Expert review of pharmacoeconomics & outcomes research* 19.2 (2019), pp. 181–187. DOI: [10.1080/14737167.2019.1548279](https://doi.org/10.1080/14737167.2019.1548279).
- [90] Vahab Vahdat et al. “Calibration and validation of the Colorectal Cancer and Adenoma Incidence and Mortality (CRC-AIM) microsimulation model using deep neural networks”. *Medical Decision Making* 43.6 (2023), pp. 719–736. DOI: [10.1177/0272989X231184175](https://doi.org/10.1177/0272989X231184175).
- [91] Helen Bell Gorrod et al. “A review of survival analysis methods used in NICE technology appraisals of cancer treatments: consistency, limitations, and areas for improvement”. *Medical Decision Making* 39.8 (2019), pp. 899–909. DOI: [10.1177/0272989X19881967](https://doi.org/10.1177/0272989X19881967).
- [92] Mohammed Eslam et al. “The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease”. *Hepatology international* 14 (2020), pp. 889–919. DOI: [10.1007/s12072-020-10094-2](https://doi.org/10.1007/s12072-020-10094-2).

- [93] Aastha Jindal, Anusha Thadi, and Kunwar Shailubhai. “Hepatocellular carcinoma: etiology and current and future drugs”. *Journal of clinical and experimental hepatology* 9.2 (2019), pp. 221–232. DOI: [10.1016/j.jceh.2019.01.004](https://doi.org/10.1016/j.jceh.2019.01.004).
- [94] Vidhyaleha Chandran et al. “Hepatocellular carcinoma (HCC) is changing its face: analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia”. *Internal Medicine Journal* 53.7 (2023), pp. 1131–1136. DOI: [10.1111/imj.15689](https://doi.org/10.1111/imj.15689).
- [95] Thai P Hong et al. “Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study”. *Medical Journal of Australia* 209.8 (2018), pp. 348–354. DOI: [10.5694/mja18.00373](https://doi.org/10.5694/mja18.00373).
- [96] Mary Qian YY et al. “Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital”. *Journal of gastroenterology and hepatology* 25.5 (2010), pp. 951–956. DOI: [10.1111/j.1440-1746.2009.06203.x](https://doi.org/10.1111/j.1440-1746.2009.06203.x).